What is 10x Genomics?
Single-cell and spatial biology tools company with $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue scale.
- Category
- Single-cell and spatial biology tools
- Headquarters
- Pleasanton, CA
- Founded
- 2012
- Employees
- 1,200+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: TXG
What is 10x Genomics?
10x Genomics is a Single-cell and spatial biology tools company headquartered in Pleasanton, CA. As of June 2026, its clearest scale signal is $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue.
10x Genomics operates a life-science tools company selling instruments, consumables, and software for single-cell, spatial, and in situ biology. Its core customer set includes academic researchers, biopharma companies, translational labs, core facilities, clinical researchers, and genomics centers, and its public product surface includes Chromium, Visium, Xenium, GEM-X, Single Cell Gene Expression. The current scale signal is $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does 10x Genomics offer?
10x Genomics offers Chromium, Visium, Xenium, GEM-X and related healthcare workflows.
- Chromium· Core product
- Visium· Core product
- Xenium· Core product
- GEM-X· Workflow
- Single Cell Gene Expression· Workflow
- Immune Profiling· Workflow
- Spatial Gene Expression· Platform
- Loupe Browser· Platform
- Cloud Analysis· Platform
How does 10x Genomics make money?
10x Genomics earns instrument, consumable, software, service, and royalty revenue, with recurring pull-through tied to installed instruments and experiment volumes.
10x Genomics earns instrument, consumable, software, service, and royalty revenue, with recurring pull-through tied to installed instruments and experiment volumes. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Instrument and consumable pricing is quote-based by platform, reagent kit, sample throughput, service contract, software needs, and institutional purchasing terms. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads 10x Genomics?
10x Genomics is led by Serge Saxonov, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Serge SaxonovCo-founder and Chief Executive OfficerCEO since foundingLeads platform and product strategy.
- Justin McAnearChief Financial OfficerCFOOwns finance and investor relations.
- Michael Schnall-LevinChief Technology OfficerCTOLeads technology and platform development.
- Ben HindsonCo-founder and PresidentCo-founderScientific and platform leader for single-cell products.
How do you contact 10x Genomics's leadership?
10x Genomics publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@10xgenomics.com (official published/company IR contact); personal executive format not verifiedHow much funding has 10x Genomics raised?
10x Genomics is a public company (Nasdaq: TXG), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2012: Founded - 10x Genomics is founded to build high-resolution biology tools. 2015: Chromium launch - The company launches the Chromium single-cell platform. 2019: IPO - 10x Genomics lists on Nasdaq under TXG. 2023: Spatial portfolio expansion - Xenium and Visium broaden spatial biology exposure. 2026: 2025 results - 10x reports $642.8M of 2025 revenue including patent-settlement revenue.
As of June 2026, 10x Genomics's practical funding capacity is best read through Nasdaq: TXG, $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives 10x Genomics access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did 10x Genomics get here?
10x Genomics grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2012Company founded10x starts in Pleasanton around microfluidics and genomics.
- 2015Chromium commercializedSingle-cell analysis becomes the flagship platform.
- 2019Public listing10x lists on Nasdaq.
- 2020Visium scalesSpatial transcriptomics becomes a second growth pillar.
- 2023Xenium launchesIn situ spatial platform adds tissue imaging workflows.
- 2025Revenue $642.8M10x reports full-year revenue including litigation-settlement revenue.
Who are 10x Genomics's competitors?
10x Genomics competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- RevvityLife-science tools and diagnostics company with research workflow adjacencies.
- Bio-RadLife-science tools and clinical-diagnostics company with droplet and single-cell adjacencies.
- BDFlow cytometry, single-cell multiomics, and clinical-lab instrument competitor.
- Parse BiosciencesSingle-cell sequencing workflow competitor with fixation-first sample prep.
- BrukerScientific-instrument company with spatial biology assets through NanoString.
- Standard BioToolsMass cytometry and spatial biology tools competitor.
10x Genomics — frequently asked questions
